Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies

Abstract

The indolizidine alkaloid swainsonine, a potent inhibitor of Golgi α- mannosidase II, has been shown to reduce tumor cell metastasis, enhance cellular immune responses, and reduce solid tumor growth in mice. In our previous Phase I study, swainsonine administered by 5-day continuous infusion inhibited L-phytohemagglutinin-reactive N-linked oligosaccharide expression on peripheral blood lymphocytes. Significant toxicities included edema and elevated serum aspartate aminotransferase (AST). One patient with head and neck cancer had objective (>50%) tumor remission. Two patients showed symptomatic improvement. The objectives of this Phase lB trial were to examine the pharmacokinetics, toxicities, and biochemical effects of biweekly oral swainsonine at escalating dose levels (50-600 μg/kg) in 16 patients with advanced malignancies and 2 HIV-positive patients unsuitable for conventional therapy. Eastern Cooperative Oncology Group performance status was ≤2. The maximum tolerated dose was defined as 300 μg/kg/day due primarily to serum AST abnormalities and dyspnea. Other adverse events present in >20% of patients included increase in serum AST (all patients), fatigue (n = 9), anorexia (n = 6), dyspnea (n = 6), and abdominal pain (n = 4). Inhibition of Golgi α-mannosidase II occurred in a dose-dependent manner. Examination of immunological parameters revealed a transient decrease in CD25 + peripheral blood lymphocytes and, in seven of eight patients, an increase in CD4 +:CD8 + ratios at 2 weeks. Serum drug levels peaked 3-4 h following a single oral dose in most patients and were proportional to dose at levels ≤150 μg/kg. We conclude that oral swainsonine is tolerated by chronic intermittent administration at doses up to 150 μg/kg/day. Adverse events considered drug related were similar to those observed in the infusional study but with fatigue and neurological effects also noted. Investigations of alternative dosing schedules with low starting doses are suggested for further clinical testing.